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Abstract. The squid giant synapse is a well-defined ex-
perimental preparation for the study of ligand-dependant
synaptic transmission. Its large size gives direct experimen-
tal access to both presynaptic and postsynaptic junctional
elements, allowing direct optical, biophysical, and electro-
physiological analysis of depolarization-release coupling.
However, this important model has not been utilized in
pharmacological studies, other than those implementable
acutely in the in vitro condition. A method is presented for
oral administration of bioactive substances to living squid.
Electrophysiological characterization and direct determina-
tion of drug absorption into the nervous system demonstrate
the administration method described here to be appropriate
for pharmacological research.
Introduction
The squid Loligo pealei LeSueur, 1821 has long been a
remarkable experimental model for exploration of funda-
mental questions in neuroscience. Many aspects of the ac-
tion potential, synaptic transmission, and fast axonal trans-
port have been worked out in detail in the squid (Young,
1939; Bulloch, 1948; Bloedel et al., 1966; Katz and Miledi,
1967; Kusano et al., 1967; Llinas et al., 1981; Augustine et
al., 1985; Serulle et al., 2007). The scale of the axon and the
synaptic structures allows unparalleled access for experi-
ments. However, the synaptic and axonal experiments in the
squid have historically been limited to acute preparations,
precluding use of experimental conditions that require pro-
longed exposure. Here we describe a method for adminis-
tering water-soluble drugs and reagents parenterally to
small squid suitable for use in synaptic physiology experi-
ments. Protocols for administering a drug by intubation and
absorption through the squid digestive system are described
in some detail, and alternative approaches are considered.
The method is suitable for treatments administered 1–2 days
ahead of a challenge and was validated using the previously
described acute 1-methyl-4-phenylpyridinium (MPP) ex-
posure paradigm prior to treatment with a neuroprotective
agent. The level of the neuroprotective agent at the synapse
at the time of electrophysiological analysis was determined
and found to be in the effective range, and significant
protective effect was documented.
The technique described here is part of a study concern-
ing the neuroprotective properties that a compound (T-817)
developed by Toyama Chemical Company, Japan, has
against the toxic effect of intraxonal injection of MPP, a
substance known to produce synaptic transmission failure in
squid (Serulle et al., 2007).
Squid digestive system
The digestive system starts with a sharp parrot-like beak
leading to an esophagus 8.6 cm long and 0.6 cm wide.
Pharmaco-active substances to be administered are deliv-
ered directly into the muscular stomach via a cannula in-
serted down the esophagus, and are absorbed at the caecum
level (see Fig. 1F).
Anesthesia
Our initial attempts at oral administration of pharmaceu-
ticals were performed while the animals were anesthetized
or dormant. In the first case, 0.75 mmol l1 of MS-222
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(tricaine mesilate) was added to the seawater (Frazier and
Narahashi, 1975). MS-222 is a local anesthetic that prevents
the generation and conduction of action potentials by block-
ing sodium conductance, rendering the squid immobile
(Frazier and Narahashi, 1975). This method was less than
optimal because squid survival was low and in all cases the
squid displayed ink-ejecting behavior, a sign of extreme
distress (Andrews and Tansey, 1981). In addition, some
animals were made dormant by immersing them in an ice
bath (Andrews and Tansey, 1981).
Although MS-222 was the only anesthetic administered
in this study, there are other general anesthetics that can be
used in these cephalopods. A 2% solution of ethanol and a
2%–3% solution of urethane in seawater have been cited
(Messenger et al., 1985) as useful anesthetics. However
these anesthetics do generate a pre-anesthetic excited con-
dition that traumatizes the squid, resulting in violent behav-
ior and inking similar to that seen with MS-222. After
immersion in these solutions, the animals stop breathing but
quickly begin again when placed in regular seawater (An-
drews and Tansey, 1981). Ice baths (at temperatures from
3–5 °C), in combination with ethanol or urethane, can also
be used. Under these conditions the animals do not react
violently, but the temperature must be carefully regulated: if
it dips to 2 °C the animals will die, and if it rises above 5 °C
the ice bath becomes useless (Messenger et al., 1985),
making the procedure on the whole very cumbersome to
control.
The most successful long-term anesthesia is that afforded
by 0.596 mol l1 MgCl2 administered at temperatures be-
tween 13 and 22 °C (Messenger et al., 1985). There is little
struggling or inking, showing that there is little trauma to
the squid, and animals kept under optimal temperature and
aquarium conditions survive for up to 5 days.. This mixture
may be adjusted to meet different needs: a 1:1 dilution
works as a surgical anesthesic, and a 1:9 can be used for
long-term sedation for shipping (Messenger et al., 1985).
Ultimately, however, we decided that the best strategy was
to intubate the animal without anesthesia, as the method is
less stressful and rapid enough to afford only minimum
discomfort to the squid.
Materials and Methods
Animals
The squid used in these experiments, Loligo pealei, were
captured off the coast of Woods Hole in June and July of
2008. Female squid of about 65 g were used. They were
kept in a 17 °C, 70-gallon tank for about 2 days, during
which they were given either one or two doses of the
experimental drug. The seawater was kept at a pH near 7.2.
After 2 days, the stellate ganglion was isolated and the
synapse prepared for electrophysiological and ultrastruc-
tural analysis.
Restraint and intubation apparatus
A squid was first gently placed into a 60-ml syringe tube.
This tube was placed in a plastic bottle to hold the squid
vertically (Fig. 1A, B). With the squid held in this position,
there was direct access to the beak and good visualization
for cannula insertion.
The cannula was made from a Tygon tube (0.76-mm
diameter) with a smooth, bulbous tip made by attaching a
fine elastic tube segment to the end of the Tygon tube. The
cannula was attached directly to a 1-ml syringe, affording
simple and fast gastric administration of a measured dose of
medication. Intubation was rapid, and the viability of the
squid was as good as that of the non-intubated controls.
Neither the restraint nor the intubation apparatus appeared
to hurt the squid.
Administration of pharmacologically active substances
Drugs were administered to the squid using an eight-step
procedure.
1. Prepare the stand as described above (Fig. 1A).
2. Place a squid in the stand by gently letting it slide
through your hands into the syringe tube, making sure
that the squid’s siphon is facing away from you.
3. Hook the top beak with fine forceps and gently pull
upward (Fig. 1B).
4. Hold the bottom of the throat bulb with blunt forceps,
keeping the fine forceps hooked on the upper beak
(Fig. 1C).
5. Slide the fine forceps between the beaks and hold the
mouth open.
6. Carefully slide the intubation canula down the esoph-
agus (located next to the lower beak, which should be
nearest to you if the siphon is pointing away from
you). Slide the tube until its end is touching the
opening of the squid’s esophagus (Fig. 1D). If an
esophageal spasm occurs while the tube is being
pushed, carefully raise the beak. If this does not work,
Figure 1. Squid intubation (A). Upper panel, intubation canula (top). Lower left syringe body serving as
squid holder (left); plastic jar (right) serving as the syringe body holder. (B) Detail of top beak being hooked with
fine tweezers. (C) Image of blunt tweezers holding the bottom of the throat bulb and fine tweezers keeping the
beak open. (D) Red arrow points to esophagus. (E) Sliding tube down esophagus till the tube stop reaches the
beginning of the esophagus. (F) Image of canula path down esophagus and methyl-blue-stained fluid in gastric
cavity.
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remove the canula and return the squid to the holding
tank.
7. Slowly empty the syringe contents into the stomach,
take out the canula, and place the squid back in the
holding tank.
8. If the squid has trouble swimming, gently squeeze the
mantle to remove any air that may have entered the
mantle hood cavity (Fig. 1E).
Pharmaceuticals
One group of 10 squid was fed 0.25 ml of 3.68 mmol l1
T-817. A second group of squid was fed twice (at a 24-h
interval) 0.25 ml of 36.8 mmol l1 T-817. T-817 is a
neuroprotective compound developed by Toyama Chemical
of Japan (Hirata et al., 2005).
MPP presynaptic microinjection and visualization
Presynaptic electrodes were filled with 0.5 mmol l1
MPP dissolved in an electrode solution containing potas-
sium acetate (0.625 mol l1), HEPES, and rhodamin dex-
tran. The last is a fluorescent tracer used to track the
movement of the injected material along the terminal.
MPP was introduced into the terminal using pressure
injections.
Diffusion of the injected fluid was monitored using a
Videcon CCD camera attached to a high-gain microchannel
plate-image intensifier, allowing the imaging of the intra-
terminal fluorescence. The images were captured and ana-
lyzed on a Hamamatsu C 1966 VIM image analysis system
(Llinas et al., 1991).
Drug absorption determination
Two paradigms were used. In the first, synaptic transmis-
sion was tested 24 h after a single oral administration of
T-817 (3.68 mmol l1) to the squid. In the second, synaptic
transmission was tested after two oral administrations of
T-817 (36.8 mmol l1), the first at 23 h and the second at 1 h
prior to synapse isolation. After the animals were sacrificed,
Figure 2. Image obtained 50 min after the microinjection of a mixture of MPP, K acetate, HEPES, and
rhodamin dextran into the presynaptic terminal.
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the optic lobes were rapidly dissected from the animals and
frozen at 70 °C. The procedure to determine drug con-
centration involved sonication (SEIKO Instruments, Chiba,
Japan) and centrifugation to obtain a purified solid sample
extracted according to the manufacturer’s manual (Oasis
HLB: Waters, Tokyo, Japan). The concentration of T-817
was measured at room temperature using HPLC.
Results
Mortality
Mortality rates were the same for intubated and non-
intubated squid and were solely related to the initial condi-
tion of the squid.
Concentration of T817 in optic lobes
To test the absorption and final concentration of T-817
within the cephalopod nervous system, the optic lobes of
control and fed squid were studied. In those squid fed one
3.68 mmol l1 dose of T-817 and sacrificed 1 day later (first
group), the final HPLC-determined concentration of T-817
was 0.21 mol l1 (n  13), indicating that 1.49% of the
compound was still present in the nervous system 1 day
after administration of a low dose.
In the squid given two 36.8 mmol l1 doses of T-817
24-h apart (second group), HPLC analysis indicated a final
optic lobe concentration of 26.7 mol l1 (n  10 squid).
No T-817 was detected in 10 control squid.
MPP presynaptic microinjection
Intraterminal injection was performed after impalement
at the presynaptic terminal with a sharp microelectrode. The
total volume injected was determined to be 0.5 to 1 pL
(Llinas et al., 1991). A typical image of the presynaptic
terminal 50 min after the initial injection is shown in Figure
2. The image indicates that the injected fluid had permeated
the entire extent of the presynaptic terminal.
Electrophysiology
Simultaneous electrophysiological recordings were made
from the presynaptic and postsynaptic terminals of the giant
synapse, following our standard procedure (Llinas et al.,
1981). Injection of MPP into the terminal was monitored
electrically as well as visually (Fig. 2) to assure terminal
viability. Chemical transmission was tested using direct
electrical stimulation of the preterminal axon with a bipolar
electrode placed over the presynaptic axon bundle. This
resulted in the generation of a presynaptic spike and a
subsequent postsynaptic response. Under normal condi-
tions, synaptic transmission will remain unchanged for 4 h
or more. In these experiments, injection of MPP, as pre-
viously reported (Serulle et al., 2007), resulted in a rapid
block of synaptic transmission (illustrated in Fig 3). After
the oral administration of T-817 to the squid, the time for
such a block was increased by a factor of 3, indicating that
the drug had the expected neuroprotective effect (Fig. 3).
Discussion
The effect of MPP injected in the presynaptic terminal
is illustrated in Figure 3A. Under such conditions, synaptic
transmission lasts for about 30 min after injection, given
pulse delivery once every 5 min. Synaptic transmission
obtained from a squid fed T-817 before a MPP injection
similar to that illustrated in Figure 3A is presented in Figure
3B. In these cases, transmission failure occurred 4 times
more slowly than in the control experiment, indicating that
oral feeding is successful as a drug delivery system. These
results corroborate the drug concentration findings follow-
ing chemical analysis of the brain tissue. The detailed elec-
trophysiological and toxicological effects of T-817 will be
published in a subsequent paper. The results presented in
Figure 3 are only examples to show that the oral adminis-
Figure 3. (a) The time course of chemical transmission failure in the
“control” group. (b) The time course of synaptic transmission failure in
squid having received two 36.8 mmol l1 injections of T817 at a 24-h
interval.
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tration method described here was effective in delivering
the drug to the animals. Thus, this paper does not detail, nor
is it a reference to, the actual effect of T-817.
In short, this simple technique affords new possibilities
for the study of pharmacological medium-term effects on
synaptic transmission in the squid giant synapse.
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